Status:
COMPLETED
Study Evaluating the Cost of the Treatments of the Refractory Psoriatic Arthritis to the Conventional Therapy
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Psoriatic, Psoriasis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to conduct an economic analysis on the cost of conventional therapy as compared to biologic therapy and the direct/indirect costs of disease management in patients with re...
Eligibility Criteria
Inclusion
- Eighteen years of age or older
- Inflammatory arthropathy associated with psoriasis meet the ACR criteria for PsA
- Patients with diagnosis of active and progressive PsA who have failure with conventional treatments
Exclusion
- Significant concurrent medical diseases including cancer or a history of cancer, uncontrolled congestive heart failure, myocardial infarctions within 12 months or other clinically significant cardiovascular diseases, immunodeficiency syndromes or concomitant infectious diseases.
Key Trial Info
Start Date :
February 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
107 Patients enrolled
Trial Details
Trial ID
NCT00303186
Start Date
February 1 2005
End Date
June 1 2011
Last Update
July 30 2012
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Cagliari, Cagliari, Italy, 09100
2
Pfizer Investigational Site
Napoli, Campania, Italy, 80131
3
Pfizer Investigational Site
Prato, FI - Italy, Italy, 50047
4
Pfizer Investigational Site
Florence, Italy, Italy, 50139